Russian medical media Medvestnik cited a report from Fortune Business Insights covering the global market for fetal and neonatal diagnostic and therapeutic devices. For Chinese medical device manufacturers making overseas expansion decisions, the key takeaway is not the overall market size of USD 8.13 billion, but rather: which regions hold the revenue potential, who dominates the market, and what opportunities remain for Chinese brands.
The underlying demand driver is robust: data from NCBI (June 2025) shows approximately 13.4 million preterm infants are born worldwide each year, with roughly 1 in 10 deliveries resulting in preterm birth. Rigid clinical demand for high-risk neonatal care, alongside hospital equipment replacement cycles and ongoing NICU expansion, supports the stable 6.7% growth rate.
Assessment for Chinese manufacturers：This represents a long-term blue ocean market, but it is not a quick-win opportunity. Success requires local distributor partnerships, full understanding of local health ministry tender rules, and alignment with World Bank, Asian Development Bank or government infrastructure projects. Isolated sales efforts are difficult; this space suits enterprises with established overseas teams or those working with local service providers.
The takeaway for Chinese enterprises: selling hardware alone is insufficient. Bundled packages including training, after-sales support and consumables are essential. The ability to deliver a complete deployment-training-maintenance solution often decides order success, more so than device specifications alone.
Allocate limited compliance budgets and overseas teams first to Asia-Pacific and middle-to-high-income countries along the Belt and Road Initiative. These markets are actively expanding NICU capacity, are price-sensitive and receptive to Chinese brands, making them areas where orders can be secured within 2–3 years.
Russia requires RU registration, GCC states require MOH/MD registration, Southeast Asian nations each maintain unique local registration frameworks, and the EU follows MDR. Confirm your target countries first, then map out compliance pathways, rather than finalizing products before determining sales markets.
